Table 3.
Samples with discrepancy with respect to reference intervals
| Patient age, gender, and clinical history | Serum | EDTA-plasma | Lithium heparin PST | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Kappa (mg/L) | Lambda (mg/L) | K/L | Kappa (mg/L) | Lambda (mg/L) | K/L | Kappa (mg/L) | Lambda (mg/L) | K/L | |
| Discrepancy involving kappa | |||||||||
| 60 Y M, multiple myeloma, IgG kappa | 2.6 | 5.9 | 0.44 | 4.4 | 5.8 | 0.76 | 3.8 | 6.2 | 0.61 |
| 66 Y F, multiple myeloma, IgG lambda | 2.7 | 5.8 | 0.47 | 4.4 | 6.6 | 0.67 | 3.7 | 6.8 | 0.54 |
| 44 Y F, multiple myeloma, IgG lambda | 17.8 | 40.0 | 0.45 | 20.8 | 36.8 | 0.57 | 20.2 | 39.5 | 0.51 |
| 60 Y F, multiple myeloma, IgG lambda | 18.8 | 10.7 | 1.76 | 20.8 | 11.6 | 1.79 | 20.1 | 11.1 | 1.81 |
| 61 Y M, multiple myeloma, IgG kappa | 2.8 | 6.1 | 0.46 | 4.1 | 6.5 | 0.63 | 4.1 | 6.1 | 0.67 |
| 51 Y M, multiple myeloma, IgG kappa | 2.7 | 5.8 | 0.47 | 5.1 | 6.2 | 0.82 | 5.3 | 6.2 | 0.85 |
| 86 Y F, multiple myeloma, lambda light chain | 2.3 | 76 | 0.03 | 3.7 | 77.5 | 0.05 | 3.8 | 75.1 | 0.05 |
| 60 Y F, multiple myeloma, IgA lambda | 2.4 | 6.7 | 0.36 | 3.9 | 6.9 | 0.57 | 3.5 | 6.5 | 0.54 |
| 70 Y F, multiple myeloma, IgA lambda | 2.6 | 8.1 | 0.32 | 4.8 | 8.7 | 0.55 | 3.5 | 8.2 | 0.43 |
| 39 Y M, multiple myeloma, IgG lambda | 2.6 | 8.6 | 0.30 | 6.3 | 6.8 | 0.93 | 4 | 8.7 | 0.46 |
| 60 Y M, hairy cell leukemia | 19.1 | 18.7 | 1.02 | 26.1 | 19.6 | 1.33 | 21.8 | 19.7 | 1.11 |
| 62 Y M, biclonal IgG kappa + lambda light chaina | 3.1 | 1195 | <0.01 | 4.7 | 1275 | <0.01 | 3.4 | 1103 | <0.01 |
| 66 Y F, multiple myeloma, lambda light chaina | 17.0 | 296 | 0.06 | 19.7 | 263 | 0.08 | 19.3 | 359 | 0.05 |
| Discrepancy involving kappa and lambda | |||||||||
| 53 Y F, multiple myeloma, IgG kappa | 18.9 | 24.7 | 0.77 | 21.9 | 25.0 | 0.88 | 21.9 | 26.6 | 0.82 |
| 84 Y M, multiple myeloma, lamba light chain | 2.9 | 5.6 | 0.52 | 3.0 | 6.8 | 0.44 | 3.5 | 5.3 | 0.66 |
| 51 Y M, multiple myeloma, IgG kappa | 1.8 | 5.5 | 0.33 | 3.6 | 6.9 | 0.52 | 2.9 | 6.8 | 0.43 |
| Discrepancy involving kappa and kappa/lambda ratio | |||||||||
| 54 Y F, multiple myeloma, kappa light chain | 1.4 | 7.2 | 0.19 | 3.5 | 7.6 | 0.46 | 2.5 | 7.6 | 0.33 |
| Discrepancy involving kappa/lambda ratio | |||||||||
| 67 Y M, multiple myeloma, IgG kappa | 29.1 | 18.3 | 1.59 | 34.4 | 18.4 | 1.87 | 29.3 | 18.5 | 1.58 |
| 64 Y M, multiple myeloma, kappa light chain | 21.9 | 13.8 | 1.59 | 23.7 | 14.9 | 1.59 | 25.1 | 13.9 | 1.81 |
| 57 Y F, multiple myeloma, IgG lambda | 25.1 | 15.7 | 1.60 | 27.7 | 15.6 | 1.78 | 26.2 | 15.5 | 1.69 |
| 55 Y M, multiple myeloma, lambda light chain | 12.1 | 7.4 | 1.64 | 14.8 | 7.5 | 1.97 | 13.9 | 7.4 | 1.88 |
| 59 Y M, Waldenstroms, IgM lambda | 19.8 | 12.6 | 1.57 | 22.7 | 12.7 | 1.79 | 23.5 | 12.9 | 1.82 |
PST plasma separator tube
aAlso identified as outlier for lambda light chain analysis by Deming regression (Table 4)